Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Revenues Beat

Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results

January 31, 2018 4:05 PM EST

-Total 2017 CF product revenues of $2.17 billion, a 29% increase compared to $1.68 billion in 2016; 2017 KALYDECO revenues of $845 million and 2017 ORKAMBI revenues of $1.32 billion-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2017.

Key financial results include:

                 

Three Months EndedDecember 31,

%

Twelve Months EndedDecember 31,

% 2017     2016 Change 2017     2016 Change (in millions, except per share and percentage data) ORKAMBI product revenues, net $ 365 $ 277 32% $ 1,321 $ 980 35% KALYDECO product revenues, net $

256

$

177

44% $

845

$

703

20% TOTAL CF product revenues, net $

621

$

454

... More